vs
INTERNATIONAL BANCSHARES CORP（IBOC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
INTERNATIONAL BANCSHARES CORP的季度营收约是再鼎医药的1.7倍（$217.7M vs $127.1M），再鼎医药同比增速更快（17.1% vs 4.5%），INTERNATIONAL BANCSHARES CORP自由现金流更多（$472.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.8%）
国际银行股份公司（International Bancshares Corporation）是总部位于美国得克萨斯州拉雷多的银行控股公司，核心子公司为国际商业银行。目前集团通过旗下银行子公司运营217个营业网点、315台自动柜员机，服务覆盖得克萨斯州、俄克拉荷马州的88个城镇社区。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
IBOC vs ZLAB — 直观对比
营收规模更大
IBOC
是对方的1.7倍
$127.1M
营收增速更快
ZLAB
高出12.6%
4.5%
自由现金流更多
IBOC
多$499.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $217.7M | $127.1M |
| 净利润 | $106.9M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 62.8% | -54.6% |
| 净利率 | 62.3% | — |
| 营收同比 | 4.5% | 17.1% |
| 净利润同比 | -7.1% | — |
| 每股收益（稀释后） | $1.71 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBOCZLAB
| Q4 25 | $217.7M | $127.1M | ||
| Q3 25 | $218.1M | $115.4M | ||
| Q2 25 | $208.2M | $109.1M | ||
| Q1 25 | $198.2M | $105.7M | ||
| Q4 24 | $208.3M | $108.5M | ||
| Q3 24 | $211.8M | $101.8M | ||
| Q2 24 | $207.8M | $100.1M | ||
| Q1 24 | $205.8M | $87.1M |
净利润IBOCZLAB
| Q4 25 | $106.9M | — | ||
| Q3 25 | $108.4M | $-36.0M | ||
| Q2 25 | $100.1M | $-40.7M | ||
| Q1 25 | $96.9M | $-48.4M | ||
| Q4 24 | $115.1M | — | ||
| Q3 24 | $99.8M | $-41.7M | ||
| Q2 24 | $97.0M | $-80.3M | ||
| Q1 24 | $97.3M | $-53.5M |
毛利率IBOCZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率IBOCZLAB
| Q4 25 | 62.8% | -54.6% | ||
| Q3 25 | 62.6% | -42.3% | ||
| Q2 25 | 60.5% | -50.3% | ||
| Q1 25 | 61.1% | -53.3% | ||
| Q4 24 | 64.2% | -62.6% | ||
| Q3 24 | 60.0% | -66.6% | ||
| Q2 24 | 60.1% | -76.0% | ||
| Q1 24 | 59.9% | -80.7% |
净利率IBOCZLAB
| Q4 25 | 62.3% | — | ||
| Q3 25 | 49.7% | -31.2% | ||
| Q2 25 | 48.1% | -37.3% | ||
| Q1 25 | 48.9% | -45.8% | ||
| Q4 24 | 71.5% | — | ||
| Q3 24 | 47.1% | -40.9% | ||
| Q2 24 | 46.7% | -80.2% | ||
| Q1 24 | 47.3% | -61.4% |
每股收益（稀释后）IBOCZLAB
| Q4 25 | $1.71 | $-0.05 | ||
| Q3 25 | $1.74 | $-0.03 | ||
| Q2 25 | $1.61 | $-0.04 | ||
| Q1 25 | $1.56 | $-0.04 | ||
| Q4 24 | $1.85 | $-0.09 | ||
| Q3 24 | $1.60 | $-0.04 | ||
| Q2 24 | $1.56 | $-0.08 | ||
| Q1 24 | $1.56 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.5B | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $715.5M |
| 总资产 | $16.6B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IBOCZLAB
| Q4 25 | $5.5B | $689.6M | ||
| Q3 25 | $5.6B | $717.2M | ||
| Q2 25 | $5.8B | $732.2M | ||
| Q1 25 | $5.6B | $757.3M | ||
| Q4 24 | $5.4B | $779.7M | ||
| Q3 24 | $5.8B | $616.1M | ||
| Q2 24 | $5.7B | $630.0M | ||
| Q1 24 | $5.7B | $650.8M |
股东权益IBOCZLAB
| Q4 25 | $3.3B | $715.5M | ||
| Q3 25 | $3.1B | $759.9M | ||
| Q2 25 | $3.0B | $791.7M | ||
| Q1 25 | $2.9B | $810.8M | ||
| Q4 24 | $2.8B | $840.9M | ||
| Q3 24 | $2.7B | $667.7M | ||
| Q2 24 | $2.6B | $704.2M | ||
| Q1 24 | $2.5B | $762.2M |
总资产IBOCZLAB
| Q4 25 | $16.6B | $1.2B | ||
| Q3 25 | $16.6B | $1.2B | ||
| Q2 25 | $16.5B | $1.2B | ||
| Q1 25 | $16.3B | $1.2B | ||
| Q4 24 | $15.7B | $1.2B | ||
| Q3 24 | $15.9B | $985.3M | ||
| Q2 24 | $15.5B | $987.4M | ||
| Q1 24 | $15.4B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $491.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $472.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 217.2% | -21.0% |
| 资本支出强度资本支出/营收 | 8.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.59× | — |
| 过去12个月自由现金流最近4个季度 | $809.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流IBOCZLAB
| Q4 25 | $491.1M | $-26.0M | ||
| Q3 25 | $115.2M | $-32.0M | ||
| Q2 25 | $95.5M | $-31.0M | ||
| Q1 25 | $140.5M | $-61.7M | ||
| Q4 24 | $473.9M | $-55.8M | ||
| Q3 24 | $116.5M | $-26.8M | ||
| Q2 24 | $107.2M | $-42.2M | ||
| Q1 24 | $135.4M | $-90.1M |
自由现金流IBOCZLAB
| Q4 25 | $472.9M | $-26.7M | ||
| Q3 25 | $112.2M | $-35.0M | ||
| Q2 25 | $91.6M | $-33.9M | ||
| Q1 25 | $133.1M | $-63.2M | ||
| Q4 24 | $459.8M | $-58.4M | ||
| Q3 24 | $109.6M | $-28.2M | ||
| Q2 24 | $104.9M | $-42.9M | ||
| Q1 24 | $128.9M | $-91.1M |
自由现金流率IBOCZLAB
| Q4 25 | 217.2% | -21.0% | ||
| Q3 25 | 51.5% | -30.4% | ||
| Q2 25 | 44.0% | -31.1% | ||
| Q1 25 | 67.1% | -59.9% | ||
| Q4 24 | 220.8% | -53.8% | ||
| Q3 24 | 51.7% | -27.7% | ||
| Q2 24 | 50.5% | -42.9% | ||
| Q1 24 | 62.6% | -104.5% |
资本支出强度IBOCZLAB
| Q4 25 | 8.3% | 0.5% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 3.7% | 1.5% | ||
| Q4 24 | 6.8% | 2.4% | ||
| Q3 24 | 3.3% | 1.3% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 3.2% | 1.1% |
现金转化率IBOCZLAB
| Q4 25 | 4.59× | — | ||
| Q3 25 | 1.06× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 1.45× | — | ||
| Q4 24 | 4.12× | — | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 1.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBOC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
